Categorization of Alzheimer's disease stages using deep learning approaches with McNemar's test

利用深度学习方法和 McNemar 检验对阿尔茨海默病分期进行分类

阅读:1

Abstract

Early diagnosis is crucial in Alzheimer's disease both clinically and for preventing the rapid progression of the disease. Early diagnosis with awareness studies of the disease is of great importance in terms of controlling the disease at an early stage. Additionally, early detection can reduce treatment costs associated with the disease. A study has been carried out on this subject to have the great importance of detecting Alzheimer's disease at a mild stage and being able to grade the disease correctly. This study's dataset consisting of MRI images from the Alzheimer's Disease Neuroimaging Initiative (ADNI) was split into training and testing sets, and deep learning-based approaches were used to obtain results. The dataset consists of three classes: Alzheimer's disease (AD), Cognitive Normal (CN), and Mild Cognitive Impairment (MCI). The achieved results showed an accuracy of 98.94% for CN vs AD in the one vs one (1 vs 1) classification with the EfficientNetB0 model and 99.58% for AD vs CNMCI in the one vs All (1 vs All) classification with AlexNet model. In addition, in the study, an accuracy of 98.42% was obtained with the EfficientNet121 model in MCI vs CN classification. These results indicate the significant potential for mild stage Alzheimer's disease detection of Alzheimer's disease. Early detection of the disease in the mild stage is a critical factor in preventing the progression of Alzheimer's disease. In addition, a variant of the non-parametric statistical McNemar's Test was applied to determine the statistical significance of the results obtained in the study. Statistical significance of 1 vs 1 and 1 vs all classifications were obtained for EfficientNetB0, DenseNet, and AlexNet models.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。